Adaptive Biotechnologies ADPT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $70.87M-1.1% | $71.68M-23.7% | $93.97M+59.6% | $58.88M+12.3% | $52.44M+10.5% | ||
| $18.71M+2.7% | $18.22M+0.4% | $18.16M+0.9% | $18M+6.0% | $16.98M-5.9% | ||
| $52.17M-2.4% | $53.46M-29.5% | $75.82M+85.5% | $40.88M+15.3% | $35.46M+20.6% | ||
| 73.6%-1.0pp | 74.6%-6.1pp | 80.7%+11.2pp | 69.4%+1.8pp | 67.6%+5.6pp | ||
| $23.62M+8.5% | $21.76M-8.1% | $23.67M-1.9% | $24.13M-0.3% | $24.2M+4.4% | ||
| $26.35M+7.6% | $24.48M+4.3% | $23.47M-0.4% | $23.57M+2.3% | $23.05M+6.8% | ||
| $20.98M+7.3% | $19.56M+8.9% | $17.96M+1.0% | $17.79M+2.2% | $17.4M-3.6% | ||
| $419K-2.3% | $429K+0.2% | $428K+1.2% | $423K+1.0% | $419K-2.1% | ||
| $90.08M+6.7% | $84.45M+0.9% | $83.68M-0.3% | $83.92M+2.3% | $82.05M+0.9% | ||
| -$19.21M-50.4% | -$12.77M-224% | $10.29M+141% | -$25.04M+15.4% | -$29.6M+12.5% | ||
| -27.1%-9.3pp | -17.8%-28.8pp | 10.9%+53.5pp | -42.5%+13.9pp | -56.4%+14.8pp | ||
| $2.08M-3.2% | $2.15M-3.5% | $2.23M-6.9% | $2.39M-10.8% | $2.68M-12.8% | ||
| -$20.03M-47.5% | -$13.58M-242% | $9.55M+137% | -$25.61M+14.2% | -$29.85M+11.4% | ||
| -28.3%-9.3pp | -18.9%-29.1pp | 10.2%+53.7pp | -43.5%+13.4pp | -56.9%+14.1pp | ||
| -$0.13-44.4% | -$0.09-250% | $0.06+135% | -$0.17+15.0% | -$0.20+9.1% | ||
| -$0.13-44.4% | -$0.09-250% | $0.06+135% | -$0.17+15.0% | -$0.20+9.1% | ||
| 155.5M+2.5% | 151.7M-7.0% | 163.2M+7.3% | 152.1M+1.9% | 149.2M+1.4% | ||
| 155.5M+2.5% | 151.7M-0.5% | 152.4M+0.2% | 152.1M+1.9% | 149.2M+1.4% | ||
| $419K-2.3% | $429K+0.2% | $428K+1.2% | $423K+1.0% | $419K-2.1% | ||
| $2.08M-3.2% | $2.15M-3.5% | $2.23M-6.9% | $2.39M-10.8% | $2.68M-12.8% | ||
| $70.87M-1.1% | $71.68M-23.7% | $93.97M+59.6% | $58.88M+12.3% | $52.44M+10.5% | ||
| -$19.21M-50.4% | -$12.77M-224% | $10.29M+141% | -$25.04M+15.4% | -$29.6M+12.5% | ||
| -$15.37M-79.2% | -$8.58M-158% | $14.7M+172% | -$20.53M+17.4% | -$24.87M+15.4% | ||
| -$15.37M-79.2% | -$8.58M-158% | $14.7M+172% | -$20.53M+17.4% | -$24.87M+15.4% | ||
| -21.7%-9.7pp | -12%-27.6pp | 15.6%+50.5pp | -34.9%+12.6pp | -47.4%+14.5pp | ||
| -$19.21M-50.4% | -$12.77M-224% | $10.29M+141% | -$25.04M+15.4% | -$29.6M+12.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Adaptive Biotechnologies's revenue?
- Adaptive Biotechnologies (ADPT) generated $295.4M in revenue over the trailing twelve months, up 55.9% year over year.
- Is Adaptive Biotechnologies profitable?
- Adaptive Biotechnologies is not currently profitable: it reported a net loss of $49.7M over the trailing twelve months, a -16.8% net margin.
- What are Adaptive Biotechnologies's profit margins?
- Gross margin is 75.3% and operating margin is -15.8%, with a -16.8% net margin.
- What is Adaptive Biotechnologies's earnings per share?
- Adaptive Biotechnologies's diluted EPS over the trailing twelve months is $-0.33.
- Where does Adaptive Biotechnologies's income statement data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
